134 related articles for article (PubMed ID: 33046560)
1. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
[TBL] [Abstract][Full Text] [Related]
2. Metal protein attenuating compounds for the treatment of Alzheimer's dementia.
Sampson EL; Jenagaratnam L; McShane R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005380. PubMed ID: 24563468
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
[TBL] [Abstract][Full Text] [Related]
4. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
Avgerinos KI; Ferrucci L; Kapogiannis D
Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
6. Minimal clinically important difference in Alzheimer's disease: Rapid review.
Muir RT; Hill MD; Black SE; Smith EE
Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
[TBL] [Abstract][Full Text] [Related]
8. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
[TBL] [Abstract][Full Text] [Related]
9. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH; Barry HC; Baduni K; Grasso G
Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs: A Systematic Review and Meta-analysis.
Alves F; Kalinowski P; Ayton S
Neurology; 2023 May; 100(20):e2114-e2124. PubMed ID: 36973044
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of action and clinical trial results of Lecanemab (Leqembi
Niidome T; Ishikawa Y; Ogawa T; Nakagawa M; Nakamura Y
Nihon Yakurigaku Zasshi; 2024; 159(3):173-181. PubMed ID: 38692883
[TBL] [Abstract][Full Text] [Related]
13. Drug Repositioning of Pioglitazone in Management and Improving the Cognitive Function among the Patients With Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Basutkar RS; Sudarsan P; Robin SM; Bhaskar V; Viswanathan B; Sivasankaran P
Neurol India; 2023; 71(6):1132-1141. PubMed ID: 38174446
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of randomized controlled trials on the effects of exercise interventions on amyloid beta levels in humans.
Pucci IM; Aguiar AF; Pucci RM; Casonatto J; Borghi SM
Exp Brain Res; 2024 May; 242(5):1011-1024. PubMed ID: 38551691
[TBL] [Abstract][Full Text] [Related]
15. Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.
David MCB; Del Giovane M; Liu KY; Gostick B; Rowe JB; Oboh I; Howard R; Malhotra PA
J Neurol Neurosurg Psychiatry; 2022 Jul; 93(10):1080-90. PubMed ID: 35790417
[TBL] [Abstract][Full Text] [Related]
16. β-amyloid: The known unknowns.
Ayton S; Bush AI
Ageing Res Rev; 2021 Jan; 65():101212. PubMed ID: 33188924
[TBL] [Abstract][Full Text] [Related]
17. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Croop R; Lipton RB; Kudrow D; Stock DA; Kamen L; Conway CM; Stock EG; Coric V; Goadsby PJ
Lancet; 2021 Jan; 397(10268):51-60. PubMed ID: 33338437
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Treatments for Frozen Shoulder: A Systematic Review and Meta-analysis.
Challoumas D; Biddle M; McLean M; Millar NL
JAMA Netw Open; 2020 Dec; 3(12):e2029581. PubMed ID: 33326025
[TBL] [Abstract][Full Text] [Related]
19. The shared risk of diabetes between dog and cat owners and their pets: register based cohort study.
Delicano RA; Hammar U; Egenvall A; Westgarth C; Mubanga M; Byberg L; Fall T; Kennedy B
BMJ; 2020 Dec; 371():m4337. PubMed ID: 33303475
[TBL] [Abstract][Full Text] [Related]
20. Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.
Vardeny O; Kim K; Udell JA; Joseph J; Desai AS; Farkouh ME; Hegde SM; Hernandez AF; McGeer A; Talbot HK; Anand I; Bhatt DL; Cannon CP; DeMets D; Gaziano JM; Goodman SG; Nichol K; Tattersall MC; Temte JL; Wittes J; Yancy C; Claggett B; Chen Y; Mao L; Havighurst TC; Cooper LS; Solomon SD;
JAMA; 2021 Jan; 325(1):39-49. PubMed ID: 33275134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
